20.500.12556/DiRROS-31978 Symptom improvement with BDP/FF/G fixed triple inhalation powder in moderate to severe COPD patients uncontrolled with dual therapies a non-interventional, open-label, single-arm, prospective study (RESPONSE Slovenia) People living with COPD are frequently inadequately treated due to underdiagnosis ormisdiagnosis. The aim of this study was to evaluate the real-world performance of thebeclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) fixed triplecombination formulated in a dry powder inhaler (DPI) in improving symptoms, lungfunction, and adherence in moderate to severe COPD patients uncontrolled on dualtherapies. We conducted a non-interventional, open-label, single-arm, multicenter,prospective study across 19 outpatient centers in Slovenia. The primary objective was tomeasure symptom improvement with the COPD Assessment Tool (CAT). A total of 359patients with moderate to severe COPD (97% classified as GOLD E, frequent exacerbators)were followed for 24 weeks. There was a significant 6-point reduction in the CAT score afterswitching from dual therapies to BDP/FF/G inhalation powder (95% CI: −7.0 to −5.5;p < 0.0001). FEV1 increased by 110 mL (95% CI: 90–130; p < 0.0001) and FVC by 95 mL (95%CI: 65–120; p < 0.0001), reaching a statistically significant improvement of 2.5 percentagepoints in the FEV1/FVC quotient. The net improvement in dyspnea severity was 50.9%(95% CI 44.7%–57.2%), as assessed using the modified Medical Research Council (mMRC)Scale. Treatment adherence improved significantly after 6 months of triple therapy. In ourcohort, switching uncontrolled moderate-to-severe COPD patients from dual therapy toBDP/FF/G fixed triple inhalation powder led to significant improvements in symptoms,lung function, dyspnea, sleep quality, and treatment adherence. chronic obstructive pulmonary disease therapy COPD Assessment Tool kronična obstruktivna pljučna bolezen zdravljenje vprašanik za oceno kronične obstruktivne pljučne bolezni true false true Angleški jezik Slovenski jezik Neznano 2026-08-24 09:31:36 2026-08-24 09:31:37 2026-08-25 04:38:08 0000-00-00 00:00:00 2026 0 0 Nasl. z nasl. zaslona; Opis vira z dne 24. 8. 2026; str. 1-13 issue 1 Vol. 23 2026 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.24 1541-2563 10.1080/15412555.2026.2681198 288585987 RAZ_Harlander_Matevz_2026.pdf RAZ_Harlander_Matevz_2026.pdf 1 AAF85E63BFBCBEEF96C9E15BACB1CF9D 5657ba9497c1ce39d5f0baa0c842ea9c1b02f0c63ac286d3d5c7cb636e5d6177 fe0590b9-9f8d-11f1-af5a-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=49799 https://www.tandfonline.com/doi/full/10.1080/15412555.2026.2681198 1 df3409db-9f8d-11f1-af5a-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=49798 Univerzitetni klinični center Ljubljana 0 0 0